ReviewJournal of the American Chemical Society2023
Ruthenium-Based Photoactivated Chemotherapy.
Review in Journal of the American Chemical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Lighting up cancer: latest discoveries in ruthenium(ii) polypyridyl complexes for anticancer photodynamic therapy.RSC advances · 2026Review
- Uncaging Iridium(III) Complexes for Combined Photodynamic and Photoactivated Chemotherapy.Angewandte Chemie (International ed. in English) · 2026Article
- Subcellular photochemistry for precision spatial protein targeting.Nature reviews. Chemistry · 2026Review
- A Molecular Trimming Strategy for Hypoxia-Tolerant Photosensitizers With Enhanced cGAS-STING Activation.Angewandte Chemie (International ed. in English) · 2026Article
- Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation.Journal of the American Chemical Society · 2026Article
- Oxygen-Dependent Light-Induced Lipid Membrane Perturbation by TLD1433 as a Potential Contributor to Phototoxicity.Inorganic chemistry · 2026Article
- UV photo-uncaging of Ru(II)-polypyridyl bioconjugates in high vacuum.Physical chemistry chemical physics : PCCP · 2026Article
- Enhancing the Antimicrobial Photodynamic Activity of Heteroleptic Ruthenium(II) Complexes: Role of AsymmetricInorganic chemistry · 2026Article
- Image-guided activation of drugs with electromagnetic radiation.Nature chemical biology · 2026Review
- Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications.RSC medicinal chemistry · 2026Review
- Near-infrared (NIR)-responsive activation of Ru-benziphthalocyanine complexesChemical science · 2026Article
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- DFT Insights on Ligand Photodissociation Pathways in Ruthenium-Terpyridine Complexes:Inorganic chemistry · 2026Article
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- Optimized Xanthenium Photocages with Fused Ring Systems for Photoactivated Chemotherapy and G Protein-Coupled Receptor Photopharmacology.Journal of the American Chemical Society · 2026Article
- Disulfide-Bridged Ru Complex-Mediated Photo-Disulfidptosis for Colorectal Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Organophosphides: A New Class of Luminophore Ligands for Copper(I) Carbene Based TADF Emitters and Photocatalysts.Angewandte Chemie (International ed. in English) · 2026Article
- Article
- Photoredox Unmasking of Aromatic C-H Bonds in Living Environments Enabled by Thianthrenium Salts.Journal of the American Chemical Society · 2026Article
- Naphthoquinone-derived tridentate Ru(II) and Os(II) organometallics with exceptional cytotoxicity: synthesis, characterization, stability in aqueous solution and biologicalDalton transactions (Cambridge, England : 2003) · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruthenium(II) polypyridyl complexes form a vast family of molecules characterized by their finely tuned photochemical and photophysical properties. Their ability to undergo excited-state deactivation via photosubstitution reactions makes them quite unique in inorganic photochemistry. As a consequence, they have been used, in general, for building dynamic molecular systems responsive to light but, more particularly, in the field of oncology, as prodrugs for a new cancer treatment modality called photoactivated chemotherapy (PACT). Indeed, the ability of a coordination bond to be selectively broken under visible light irradiation offers fascinating perspectives in oncology: it is possible to make poorly toxic agents in the dark that become activated toward cancer cell killing by simple visible light irradiation of the compound inside a tumor. In this Perspective, we review the most important concepts behind the PACT idea, the relationship between ruthenium compounds used for PACT and those used for a related phototherapeutic approach called photodynamic therapy (PDT), and we discuss important questions about real-life applications of PACT in the clinic. We conclude this Perspective with important challenges in the field and an outlook.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.